Acomplia (rimonabant), marketed by Sanofi-Aventis is a selective CB1 endocannabinoid receptor antagonist for the treatment of obesity. The mechanism for blocking endogenous cannabinoid binding to neuronal CB1 receptors.
What is endocannabinoid system?
The endocannabinoid system in the part of the brains, metabolism, energy levels and appetite.With reference to the above drug, the endocannabinoid receptors on activation is regulated at the appetite. Therefore, drugs like Acomplia (rimonabant) for the endocannabinoid receptor blocking agent, which eventually led to a decrease in appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a new therapeutic approach to appetite control and weight loss
So what is obesity?
Overweight is defined based on the medical body mass index, individual kilogram body weight by the square of height in m / 2 is divided. For example, a BMI from 18.5 to 25 percent of the optimum weight, a BMI lower than 18.5 suggests the person is underweight while a number above 25 may indicate the person is overweight, a BMI below 17.5 may indicate the person has anorexia or a related disease, a number above 30 suggests the person is obese (more than 40, morbid obesity). So technically, their body mass index of 30 and above tend to fall into the high-risk zone. It arises from the accumulation of excess fat in the body from over consumption of fatty foods and is now one of the most common nutritional disorder in the world.
Recent studies have shown that obesity is a silent killer. It is associated with cardiovascular disease, particularly angina pectoris and myocardial infarction, atherosclerosis and arteriosclerosis leading to cerebrovascular accidents / strokes. They also cause pain in the joints and are also associated with certain cancers such as breast or colon. The proportion of obese people in developed countries has reached epidemic proportions. To this picture into better perspective, statistics show that one fifth of all Americans are overweight and one in three, the presence of diabetes mellitus overweight. In is a lethal combination and is known as diabetisity.
It shows more preference for type-2 diabetes mellitus.
Several therapeutic strategies have been investigated, including: * nor adrenaline and serotonin reuptake inhibitors (anorectic agents) lipase inhibitors * 3 * ß-adrenergic agonists, leptin agonists * * melanocortin-3 agonists
All these strategies have demonstrated a certain degree of success.Usually after that cannabis addicts suffer from extreme hunger, to find that smokers as “snacks”. This led to the belief that cannabinoid associated with hunger, and if this receptor suppressed this will lead to reduced appetite, which is just what the manufacturer of Acomplia (rimonabant) from Sanofi-Aventis.
Rimonabant prevents the endogenous cannabinoid binding to CB1 receptors in nerve cells. The activated CB1 receptors, stimulates the appetite. Therefore, this drug inhibits the activation of CB1 receptors and thus reduces appetite.
Side effects
1. —————————————- Nausea and vomiting, nausea, vomiting and gastrointestinal disorders were relatively common side effects of taking Acomplia. 2. Nervous —————————— this category include headache, weakness and dizziness. 3. Psychiatric disorders —————————————- Included mood swings, anxiety, depression, irritability , sleep disorders and related disorders. The current advice is that you should take this medicine if you suffer from mental problems. The drug is not suitable for people with persistent depressive illness and / or antidepressant therapy.
Contra-indications:
1. Each of hypersensitivity to the drug or one of its components. 2. The presence of liver damage. 3. Kidney 4th Age over 75 years and less than 16 years 5 Pregnant and lactating women. 6. In patients with lactose intolerance, since it Acomplia contains lactose 7th It may only be used with caution in combination with CYP3A4 inhibitors such as ketoconazole, ritonavir, clarithromycin, and related drugs. 8. It should not be prescribed to patients with untreated psychiatric disorders.
Acomplia [Rimonabant] taken for up to two years made in conjunction with diet and exercise greater weight loss than placebo, although most of the weight loss on the year in the first.
Comments Off